Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Incorporated's second quarter 2025 financial results and business update call. At this time, all participants are in listening mode. Following management's prepared remarks, we'll hold a question and answer session. To ask a question at that time, please press star followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this call is being recorded today, August 14th, 2025. At this time, I'd like to turn the call over to John Frentz of LifeSci Advisors. Thank you, Operator, and welcome everyone to TRAS Pharma's second quarter 2025 financial results and business update conference call. This morning, TRAS issued a press release reporting its second quarter 2025 financial results and provided a business update. If you have not yet seen this press release, it is available in the investor relations section of the company's website. Following my introduction, we will hear from TRAS Interim Chief Executive Officer, Dr. Ian Dukes, Chief Science Officer, Dr. David Pauza, Chief Medical Officer, Dr. Robert Redfield, and Interim Chief Financial Officer, Charles Parker. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made, as the underlying facts and circumstances may change. Except as required by law, TRAS disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. For more information on forward-lo...